It is all about forwards valuations. Being conservative, the first big jump due to insto interest, will come after 2 consecutive CF+ quarters or sales which suggest those quarters will become a regular case. PE valuations of 15-30 are normal. If they could get to $2m annual profit, that x 30, a MC of $60m or a sp about 3.5-4c would be the minimum. But if the market is a bit more optimistic then 5c could be easily on the cards as well. There are many bio-devise comps trading at $200m - $2b for being close to CF+. But let's consider numbers below $100m first.
Let's see where the company's sp will be in 12 months.
GLTA
CC5 Price at posting:
2.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)